DBV Technologies Announces Results from Phase II Study of Viaskin Milk in Milk-Allergic Patients

DBV Technologies Announces Results from Phase II Study of Viaskin Milk in Milk-Allergic Patients

Positive preliminary results support Viaskin Milk's potential as the first treatment for patients suffering from IgE-mediated cow's milk protein allergy (CMPA), an unmet medical need for which there are no approved therapies 

A statistically significant desensitization to milk was observed in children ages two to 11 treated with Viaskin Milk 300 µg for 12 months

Company evaluating optimal dosing/patient population for future studies

MONTROUGE, February 26, 2018 - DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced preliminary results from Part B, or Phase II, of a Phase I/II study evaluating the efficacy and safety of three dose regimens of Viaskin Milk (150 µg, 300 µg, 500 µg) in 198 patients for the treatment of IgE-mediated cow's milk protein allergy (CMPA). The MILES (Milk Efficacy and Safety) study was designed to determine a safe and effective dose in two age groups: children ages two to 11 and adolescents ages 12 to 17.

To download the full version of the Press Release in English language, please click on the following link: PDF Version

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/df4594b4-8f4f-45e7-939d-26f615740953